Definium Therapeutics Announces Positive Phase III Results and DT120 NDA Filing Timeline
Definium Therapeutics (DFTX) reported a significant inflection point in its Q3 2026 earnings call, highlighted by positive Phase III clinical trial results across three studies targeting two major psychiatric indications. The company's lead candidate, DT120, is now on track for a New Drug Application (NDA) filing scheduled for the first half of 2027. Financially, the company reported an extended cash runway reaching into 2030, providing stability as it transitions from clinical development toward regulatory milestones. This progress marks a shift from demonstrating therapeutic promise to preparing for commercialization pathways.